🏛️ Verified NIH Record • Updated 2026-08-27
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma (NCT05050097)
A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Janssen Research & Development, LLC
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.
Who can join: Review the eligibility criteria below.
Location: University of Alabama Birmingham — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (31 Sites)
Showing the first 25 of 31 sites.
- University of Alabama Birmingham — Birmingham, Alabama
- University of California San Francisco — San Francisco, California
- Colorado Blood Cancer Institute — Denver, Colorado
- Emory University — Atlanta, Georgia
- Indiana University — Indianapolis, Indiana
- Hackensack University Medical Center — Hackensack, New Jersey
- Mt. Sinai School of Medicine — New York, New York
- Weill Cornell Medical College — New York, New York
- Levine Cancer Institute — Charlotte, North Carolina
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
- Tennessee Oncology — Nashville, Tennessee
- Medical College Of Wisconsin — Milwaukee, Wisconsin
- St Vincents Hospital Melbourne — Fitzroy,
- Alfred Health — Melbourne,
- Gold Coast University Hospital — Southport,
- Wollongong Hospital — Wollongong,
- Cliniques Universitaires St-Luc — Brussels,
- UZA — Edegem,
- UZ Gent — Ghent,
- UZ Leuven — Leuven,
- CHU Nantes — Nantes,
- CHU de Bordeaux - Hospital Haut-Leveque — Pessac,
- Chu Rennes Hopital Pontchaillou — Rennes,
- Institut Universitaire du cancer de Toulouse-Oncopole — Toulouse,
- UMCG — Groningen,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma
- Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey
Explore by condition: All Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.